Journal Information
Vol. 44. Issue 1.
Pages 29-34 (January 2008)
Share
Share
Download PDF
More article options
Vol. 44. Issue 1.
Pages 29-34 (January 2008)
Original Articles
Full text access
Mutations in the Gene Encoding Bone Morphogenetic Protein Receptor 2 in Patients With Idiopathic Pulmonary Arterial Hypertension
Visits
4156
Adolfo Baloiraa,
Corresponding author
adolfobaloira@sogapar.org

Correspondence: Dr. A. Baloira Servicio de Neumología, Complexo Hospitalario de Pontevedra Mourente, s/n, 36071 Pontevedra, Spain
, Carlos Vilariñoa, Virginia Leiroa, Diana Valverdeb,b
a Servicio de Neumología, Complexo Hospitalario de Pontevedra, Pontevedra, Spain
b Departamento de Genética, Facultad de Biología, Universidad de Vigo, Vigo, Pontevedra, Spain
This item has received
Article information
Abstract
Bibliography
Download PDF
Statistics
Objective

Pulmonary arterial hypertension (PAH) is a rare disease that can have a familial component. It has been shown that more than 50% of cases of familial PAH are associated with mutations in the gene encoding bone morphogenetic protein receptor 2 (BMPR2), which acts as a receptor for members of the transforming growth factor β superfamily. Some studies in patients with idiopathic PAH have also shown varying percentages of mutations in this gene. The aim of this study was to determine the frequency of these mutations in a group of patients with idiopathic PAH.

Patients and methods

The study population included patients with idiopathic PAH who were seen during 2006 in our unit specialized in this entity. Patients were excluded if they had relatives who had been diagnosed with PAH or who had symptoms that led to suspicion of the disease. Diagnosis was obtained according to the protocol used in our unit. A hemodynamic study was carried out in all cases and patients were included if they had a mean pulmonary arterial pressure of greater than 25 mm Hg. DNA was extracted from peripheral leukocytes and amplified by polymerase chain reaction. Seventeen primer pairs were used for the 13 exons that make up the gene. Using the single strand conformational polymorphism (SSCP) technique we detected anomalous DNA fragments for subsequent sequencing.

Results

The study included 8 patients (4 women). In 5 patients, no abnormalities were observed, whereas in the remaining 3, anomalous electrophoresis patterns were obtained in the SSCP and sequencing revealed mutations. In 1 case, 2 different electrophoresis patterns were observed by SSCP, but it was only possible to sequence 1 of them due to the low concentration of DNA obtained.

Conclusions

The presence of mutations in the gene encoding BMPR2 is not infrequent in patients with idiopathic PAH, suggesting that this family of growth factors may be important in the pathogenesis of the disease and could have therapeutic implications.

Key words:
Pulmonary arterial hypertension
BMPR2
Mutations
Objetivo

La hipertensión arterial pulmonar (HAP) es una enfermedad poco frecuente que puede tener un componente familiar. En este caso se ha comprobado que un porcentaje superior al 50% se asocia a mutaciones en el gen que codifica el receptor tipo 2 de las proteínas morfogenéticas del hueso (BMPR2), un receptor de la superfamilia del factor transformador del crecimiento beta. Algunos estudios en pacientes con HAP idiopática también muestran porcentajes variables de mutaciones en este gen. El objetivo de nuestro trabajo ha sido conocer la frecuencia de estas mutaciones en nuestros pacientes con HAP idiopática.

Pacientes y métodos

Los pacientes con HAP idiopática seguidos en nuestra unidad de HAP durante el año 2006 constituyeron la población de estudio. Se excluyó la existencia de familiares con diagnóstico de esta enfermedad o síntomas que pudieran hacer pensar en ella. El diagnóstico de HAP fue acorde con el protocolo utilizado en la unidad. En todos los casos se realizó estudio hemodinámico y se incluyó a pacientes con presión arterial pulmonar media mayor de 25 mmHg. Se efectuó extracción del ADN de los leucocitos periféricos y se amplificó mediante la técnica de reacción en cadena de la polimerasa. Se utilizaron 17 parejas de cebadores para los 13 exones que componen el gen. Mediante técnica de conformación de hebra simple y electroforesis posterior se detectaron los fragmentos anómalos, para posteriormente proceder a la secuenciación del gen mediante un lector automático.

Resultados

Se estudió a 8 pacientes (4 mujeres). En 5 de ellos no se encontraron alteraciones, pero 3 mostraron patrones anómalos en la electroforesis y en la secuenciación se observaron mutaciones. En uno de los casos se presentaron 2 patrones anómalos en la electroforesis, pero sólo fue posible secuenciar uno de ellos por la baja concentración del ADN recogido.

Conclusiones

La presencia de mutaciones en el gen que codifica BMPR2 no es infrecuente en pacientes con HAP idiopática, lo que probablemente indique un papel importante de esta familia de factores de crecimiento en la patogenia de la enfermedad y, por tanto, podría tener implicaciones terapéuticas.

Palabras clave:
Hipertensión arterial pulmonar
BMPR2
Mutaciones
Full text is only aviable in PDF
References
[1]
GE D'Alonzo, RJ Barst, SM Ayres, EH Bergofsky, BH Brundage, KM Detre, et al.
Survival in patients with primary pulmonary hypertension: results from a national prospective registry.
Ann Intern Med, 115 (1991), pp. 343-349
[2]
SP Gaine, LJ Rubin.
Primary pulmonary hypertension.
[3]
JC Caraballo, CD Martínez, R Sánchez de León.
Disfunción endotelial en la hipertensión pulmonar.
Arch Bronconeumol, 41 (2005), pp. 389-392
[4]
DT Dresdale, RJ Michtom, M Schultaz.
Recent studies in primary pulmonary hypertension.
Bull N Y Acad Med, 30 (1954), pp. 195-207
[5]
JE Loyd, RK Primm, JH Newman.
Familial primary pulmonary hypertension: clinical patterns.
Am J Rev Respir Dis, 29 (1984), pp. 194-197
[6]
Z Deng, JH Morse, SL Slager, KJ Moore, G Venetos, S Kalachikov, et al.
Familial primary pulmonary hypertension (gene PPH1) is caused by mutations in the bone morphogenetic protein receptor-II gene.
Am J Hum Gen, 67 (2000), pp. 737-744
[7]
KB Lane, RD Machado, MW Pauciulo, JR Thomson, JA Phillips III, JE Loyd, et al.
Heterozygous germline mutations in BMPR2, encoding a TGF-β receptor, cause familial primary pulmonary hypertension.
Nat Genet, 26 (2000), pp. 81-84
[8]
JH Newman, RC Trembath, JA Morse, E Grunig, JE Loyd, S Adnot, et al.
Genetic basis of pulmonary hypertension. Current understanding and future directions.
J Am Coll Cardiol, 43 (2004), pp. 33S-39S
[9]
RD Machado, MA Aldred, V James, RE Harrison, B Patel, EC Schwalbe, et al.
Mutations of the TGF-β, type II receptor BMPR2 in pulmonary arterial hypertension.
Hum Mutat, 27 (2006), pp. 121-132
[10]
R Koehler, E Grünig, MW Pauciulo, MM Hoeper, H Olschewski, H Wilkens, et al.
Low frequency of BMPR2 mutations in a German cohort of patients with sporadic idiopathic pulmonary arterial hypertension.
J Med Genet, 41 (2004), pp. e127
[11]
KE Roberts, JJ McElroy, WPK Wong, E Yen, A Widlitz, RJ Barst, et al.
BMPR2 mutations in pulmonary arterial hypertension with congenital heart disease.
Eur Respir J, 24 (2004), pp. 371-374
[12]
M Humbert, Z Deng, G Simonneau, RJ Barst, O Sitbon, M Wolf, et al.
BMPR2 germline mutations in pulmonary hypertension associated with fenfluramine derivatives.
Eur Respir J, 20 (2002), pp. 518-523
[13]
J Morse, R Barst, E Horn, N Cuervo, Z Deng, J Knowles.
Pulmonary hypertension in scleroderma spectrum of disease: lack of bone morphogenetic protein receptor-2 mutations.
J Rheumatol, 29 (2002), pp. 2379-2381
[14]
H Nunes, M Humbert, O Sitbon, JH Morse, Z Deng, JA Knowles, et al.
Prognostic factors for survival in human immunodeficiency virus-associated pulmonary arterial hypertension.
Am J Respir Crit Care Med, 167 (2003), pp. 1433-1439
[15]
M Ravnik-Glavac, D Glavac, M Dean.
Sensitivity of single-strand conformation polymorphism and heteroduplex method for mutation detection in the cystic fibrosis gene.
Human Mol Genet, 3 (1994), pp. 801-807
[16]
JD Cogan, CL Vnencak-Jones, JA Phillips, KB Lane, LA Wheeler, IM Robbins, et al.
BMPR2 gene rearrangements constitute a new cause for primary pulmonary hypertension.
[17]
RD Machado, MW Pauciulo, JR Thomson, KB Lane, NV Morgan, L Wheeler, et al.
BMPR2 haploinsufficiency as the inherited molecular mechanism for primary pulmonary hypertension.
Am J Hum Genet, 68 (2001), pp. 92-102
[18]
S Zhang, I Fantozzi, DD Tigno, ES Yi, O Platoshyn, PA Thistlethwaite, et al.
Bone morphogenetic proteins induce apoptosis in human pulmonary vascular smooth muscle cells.
Am J Physiol Lung Cell Mol Physiol, 285 (2003), pp. 740-754
[19]
N Morrell, X Yang, P Upton, K Jourdan, N Morgan, K Sheares, et al.
Altered growth responses of pulmonary artery smooth muscle cells from patients with primary pulmonary hypertension to transforming growth factor-1 and bone morphogenetic proteins.
Circulation, 104 (2001), pp. 790-795
[20]
M Izumi, Y Fujio, K Kunisada, S Negoro, E Tone, M Funamoto, et al.
Bone morphogenetic protein-2 inhibits serum deprivation-induced apoptosis of neonatal cardiac myocytes through activation of the Smad1 pathway.
J Biol Chem, 276 (2001), pp. 31133-31141
[21]
L Du, CC Sullivan, D Chu, AJ Cho, M Kido, P Walf, et al.
Signaling molecules in nonfamilial pulmonary hypertension.
N Engl J Med, 348 (2003), pp. 500-509
[22]
K Teichert-Kuliszewska, M Kutryk, MA Kuliszewski, G Karoubi, DW Courtman, L Zucco, et al.
Bone morphogenetic protein receptor-2 signaling promotes pulmonary arterial endothelial cell survival. Implications for loss-of-function mutations in the pathogenesis of pulmonary hypertension.
[23]
AI Campbell, Y Zhao, R Sandhu, DJ Stewart.
Cell-based gene transfer of vascular endothelial growth factor attenuates monocrotaline-induced pulmonary hypertension.
Circulation, 104 (2001), pp. 2242-2248
[24]
L Taraseviciene-Stewart, Y Kasahara, L Alger, P Hirth, G McMahon, J Waltenberger, et al.
Inhibition of the VEGF receptor 2 combined with chronic hypoxia causes cell death-dependent pulmonary endothelial cell proliferation and severe pulmonary hypertension.
FASEB J, 15 (2001), pp. 427-438
[25]
RM Tuder, Z Radisavljevic, KR Shroyer, JM Polak, NF Voelkel.
Monoclonal endothelial cells in appetite suppressant-associated pulmonary hypertension.
Am J Respir Crit Care Med, 158 (1998), pp. 1999-2001
[26]
RD Machado, V James, M Southwood, RE Harrison, C Atkinson, S Stewart.
Investigation of second genetic hits at the BMPR2 locus as a modulator of disease progression in familial pulmonary arterial hypertension.
[27]
JR Thomson, RD Machado, MW Pauciulo, NV Morgan, M Humbert, GC Elliott, et al.
Sporadic primary pulmonary hypertension is associated with germline mutations of the gene encoding BMPRII, a receptor member of the TGF-α· family.
J Med Genet, 37 (2000), pp. 741-745
[28]
H Morisaki, N Nakanishi, S Kyotani, A Takashima, H Tomoike, T Morisaki.
BMPR2 mutations found in Japanese patients with familial and sporadic primary pulmonary hypertension.
Hum Mutat, 23 (2004), pp. 632
[29]
M Sankelo, JA Flanagan, RD Machado, R Harrison, N Rudarakanchana, N Morrell, et al.
BMPR2 mutations have short lifetime expectancy in primary pulmonary hypertension.
Hum Mutat, 26 (2005), pp. 119-124
[30]
MA Aldred, J Vijayakrishnan, V James, F Soubrier, MA Gómez-Sánchez, G Martensson, et al.
BMPR2 gene rearrangements account for a significant proportion of mutations in familial and idiopathic pulmonary arterial hypertension.
Hum Mutat, 27 (2006), pp. 212-213
[31]
C Atkinson, S Stewart, PD Upton, R Machado, JR Thomson, RC Trembath, et al.
Primary pulmonary hypertension is associated with reduced pulmonary vascular expression of type II bone morphogenetic protein receptor.
Circulation, 105 (2002), pp. 1672-1678

This study was made possible by financial support from Laboratorios Actelion, Barcelona, Spain.

Copyright © 2008. Sociedad Española de Neumología y Cirugía Torácica (SEPAR)
Archivos de Bronconeumología
Article options
Tools

Are you a health professional able to prescribe or dispense drugs?